Symptomatic treatment of seasonal allergic conjunctivitis.
Composition:
1 ml of solution contains 0.5 mg of emedastine in the form of bisfumarate. The solution contains benzalkonium chloride (0.1 mg / ml).
Action:
A strong, selective, topical, histamine H-receptor antagonist1. When administered topically to the eye, it causes concentration-dependent inhibition of the permeability of the conjunctiva of the conjunctiva, stimulated with histamine. It does not work on adrenergic, dopaminergic and serotonin receptors. After absorption into the bloodstream, emedastine is mainly metabolised in the liver. T0,5 in the elimination phase after topical administration is 10 h. It is excreted in urine in unchanged form and metabolites.
Contraindications:
Hypersensitivity to the active substance or to any of the excipients.
Precautions:
In the case of corneal infiltrations, the use of the preparation should be discontinued and appropriate measures should be implemented. The preparation contains benzalkonium chloride, which may cause eye irritation, as well as punctate keratopathy and / or toxic ulcerative keratopathy - careful monitoring of patients who frequently or prolonged use of the drug is required. It is not recommended in patients with impaired hepatic and renal function and in patients over 65 years due to lack of testing.
Pregnancy and lactation:
The preparation can be used during pregnancy, if the dosing recommendations are followed. Use with caution during breast-feeding.
Side effects:
Common: eye pain, pruritus of the eye. Uncommon: unusual dreams, headaches, sinus headaches, taste disturbances, corneal infiltration, corneal discoloration, blurred vision, eye irritation, dry eye, feeling of a foreign body in the eyes, increased tearing, poor vision, eye congestion, rash . Frequency unknown: tachycardia.
Dosage:
Adults and children from 3 years: 1 drop to the affected eye (eyes) 2 times a day. If you use more than one eye medicine, each of these medicines should be given at least a 10-minute break. Eye Ointment should be used at the end. The preparation has not been subjected to clinical trials lasting longer than 6 weeks.
(C)
